Vanda Pharmaceuticals (VNDA) Total Non-Current Liabilities (2011 - 2026)

Vanda Pharmaceuticals has disclosed Total Non-Current Liabilities across 15 years of filings, most recently posting $142.6 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $142.6 million, up 28.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $142.6 million (up 28.18% YoY), and the FY2025 annual result was $152.2 million, up 40.86% from the prior year.
• Total Non-Current Liabilities came in at $142.6 million for Q1 2026 at Vanda Pharmaceuticals, down from $152.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $152.2 million in Q4 2025 to a low of $92.3 million in Q3 2023.
• The 5-year median for Total Non-Current Liabilities is $100.4 million (2022), against an average of $108.6 million.
• Across the five-year window, Total Non-Current Liabilities declined 9.08% in 2023 and soared 40.86% in 2025, its largest moves.
• Vanda Pharmaceuticals' Total Non-Current Liabilities stood at $100.2 million in 2022, then slipped by 5.53% to $94.7 million in 2023, then gained by 14.12% to $108.1 million in 2024, then soared by 40.86% to $152.2 million in 2025, then slipped by 6.3% to $142.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $142.6 million (Q1 2026), $152.2 million (Q4 2025), and $124.1 million (Q3 2025), per Business Quant data.